BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 780K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

11 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
7
Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.EBI
Axys Pharmaceuticals
30
Monocharged inhibitors of mast cell tryptase derived from potent and selective dibasic inhibitors.EBI
Axys Pharmaceuticals
14
Optimization of a screening lead for factor VIIa/TF.EBI
Axys Pharmaceuticals
33
Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.EBI
Axys Pharmaceuticals
23
Development of potent and selective factor Xa inhibitors.EBI
Axys Pharmaceuticals
17
Dibasic inhibitors of human mast cell tryptase. Part 3: identification of a series of potent and selective inhibitors containing the benzamidine functionality.EBI
Axys Pharmaceuticals
59
Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity.EBI
Axys Pharmaceuticals
18
Dibasic inhibitors of human mast cell tryptase. Part 1: synthesis and optimization of a novel class of inhibitors.EBI
Axys Pharmaceuticals
4
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.BDB
Axys Pharmaceuticals
18
Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.BDB
Axys Pharmaceuticals
10
A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.BDB
Axys Pharmaceuticals